Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Jul 11, 2022
Dr. Todd Johnson is the Chief Growth Officer at M2GEN an oncology-focused health informatics company. Its mission is to connect cancer patients to a precise cure using its data platform to analyze longitudinal clinical and genomic data. With a permission-based approach to data collection, M2GEN looks at the information related to the patient and from a tumor biopsy. This data analysis allows M2GEN to understand how patients respond to existing cancer treatments and gain more knowledge about the science behind cancer so that innovations and new precision medicines can be developed.
Todd elaborates, "Let's call the first the natural genome or the normal genome of a patient, also often called the germline genome. We provide information on germline as well as on the genome of the cancer. The reason why that's really important is that cancer is a disease of DNA, and it's a disease of how DNA changes over time or mutates. Those mutations are what cause a cancer to actually occur in the first place, for it to be able to evade the immune system, which is an important element of cancer progression. Then cancers can continue to mutate during the course of their life as they grow. That access to what we call serial specimens, that access to additional information about the cancer and how it continues to change from the body's normal or the patient's normal DNA, is a really important part of unlocking the mystery of what's happening here."
@M2GEN #DataScience #DataSolutions #Genomics #CancerResearch #CancerTreatment #PrecisionOncology
